GH Research PLC GHRS
19.25 USD -0.31 (-1.58%)
At closeNov 11, 2026, 6:50 PM EST
19.00 -0.25 -1.30%
After hours · Nov 11, 6:50 PM ET
19.09 Day range 19.75
12.04 52-week range 31.44
- YTD
- +51.57%
- 1 year
- +35.37%
News
seekingalpha.com GH Research Remains Undervalued Ahead Of Pivotal Phase III Program GH Research remains significantly undervalued due to the large unmet need in treatment-resistant depression and GH001's potential efficacy. While early data appears promising, and Eli Lilly's…
defenseworld.net GH Research PLC (NASDAQ:GHRS) Receives Consensus Rating of “Moderate Buy” from Analysts Shares of GH Research PLC (NASDAQ: GHRS - Get Free Report) have been assigned an average rating of "Moderate Buy" from the twelve ratings firms that are presently covering the company, MarketBeat…
seekingalpha.com GH Research: 'Buy' GH001 TRD Advancement Presses On And Expansion Opportunities I initiate coverage on GH Research PLC with a "Buy" rating, driven by renewed momentum in its GH001 program for treatment-resistant depression [TRD]. The company resolved the FDA clinical hold on its…
benzinga.com Guggenheim Maintains Buy on GH Research, Raises Price Target to $40 Guggenheim analyst Eddie Hickman maintains GH Research (NASDAQ:GHRS) with a Buy and raises the price target from $34 to $40.
benzinga.com Cantor Fitzgerald Maintains Overweight on GH Research, Raises Price Target to $40 Cantor Fitzgerald analyst Charles Duncan maintains GH Research (NASDAQ:GHRS) with a Overweight and raises the price target from $35 to $40.
benzinga.com Needham Maintains Buy on GH Research, Raises Price Target to $39 Needham analyst Ami Fadia maintains GH Research (NASDAQ:GHRS) with a Buy and raises the price target from $32 to $39.- benzinga.com GH Research Q2 EPS $(0.23) Beats $(0.30) Estimate GH Research (NASDAQ:GHRS) reported quarterly losses of $(0.23) per share which beat the analyst consensus estimate of $(0.30) by 23.33 percent. This is a 53.33 percent decrease over losses of $(0.15)…
globenewswire.com GH Research Reports Second Quarter 2026 Financial Results and Provides Business Update Alignment with FDA on CMC and device plans for Phase 3 Successfully completed GH001-HV-106 and GH001-HV-109 Phase 1 trials Further strengthening of US and EU mebufotenin patent estate Phase 2a…
benzinga.com Wells Fargo Initiates Coverage On GH Research with Overweight Rating, Announces Price Target of $44 Wells Fargo analyst Benjamin Burnett initiates coverage on GH Research (NASDAQ:GHRS) with a Overweight rating and announces Price Target of $44.
benzinga.com Why Is GH Research Stock Trading Higher on Thursday? GH Research PLC (NASDAQ:GHRS) and Definium Therapeutics Inc. (NASDAQ:DFTX) stocks are trading higher in response to Eli Lilly and Co. (NYSE:LLY) agreeing to acquire AtaiBeckley Inc. (NASDAQ:ATAI) in…
benzinga.com Why Is GH Research Stock Trading Higher on Thursday? GH Research and Definium Therapeutics stocks rose after Eli Lilly agreed to buy AtaiBeckley in a deal worth up to $3.8 billion.
benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session Gainers AtaiBeckley (NASDAQ:ATAI) stock rose 34.3% to $7.2 during Thursday's pre-market session. The market value of their outstanding shares is at $1.9 billion. Agape ATP (NASDAQ:ATPC) shares moved…
proactiveinvestors.com CleanSpark shares surge after company secures $6.6B data center lease agreement CleanSpark Inc (NASDAQ:CLSK) shares surged more than 12% after the company announced a 20-year lease agreement for its Sandersville, Georgia data center...
proactiveinvestors.com Tower Semiconductor shares jump as company announces Japan expansion to boost silicon photonics capacity Tower Semiconductor (NASDAQ:TSEM) shares rose 13% on Tuesday after the company announced a strategic expansion of its silicon photonics, silicon germanium...
proactiveinvestors.com Psychedelics guidance from the FDA set to benefit developers, including AtaiBeckley, Jefferies says The US Food and Drug Administration's finalized guidance on psychedelic drug development signals the agency remains receptive to helping developers navigate the approval process, a development that…
benzinga.com GH Research Announces Publication Of Full Results From Its Phase 2a Trial In Postpartum Depression GH Research PLC (NASDAQ:GHRS) today announced the publication of the full results from its Phase 2a trial in postpartum depression (PPD) and the acceptance of two oral presentations at the 37th World…
globenewswire.com GH Research Announces Publication of Phase 2a Postpartum Depression Results DUBLIN, June 04, 2026 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS) today announced the publication of the full results from its Phase 2a trial in postpartum depression (PPD) and the acceptance…
seekingalpha.com GH Research: Rapid Onset And Short Action Change The Treatment Paradigm GH Research is advancing GH001, an inhalable mebufotenin therapy, in treatment-resistant depression. GH Research's Phase 2b data was strong, and a global Phase 3 program is expected in 2026. While…
benzinga.com HC Wainwright & Co. Maintains Buy on GH Research, Lowers Price Target to $65 HC Wainwright & Co. analyst Patrick R. Trucchio maintains GH Research (NASDAQ:GHRS) with a Buy and lowers the price target from $70 to $65.
benzinga.com These Analysts Revise Their Forecasts On GH Research After Q1 Results GH Research PLC (NASDAQ:GHRS) reported a wider-than-expected loss for the first quarter on Thursday.
benzinga.com These Analysts Revise Their Forecasts On GH Research After Q1 Results GH Research (NASDAQ:GHRS) reported a larger loss than expected in Q1. Analysts lowered price targets, stock fell 3.4%. CEO noted progress in GH001 program.- benzinga.com Cantor Fitzgerald Maintains Overweight on GH Research, Raises Price Target to $35 Cantor Fitzgerald analyst Charles Duncan maintains GH Research (NASDAQ:GHRS) with a Overweight and raises the price target from $25 to $35.
- benzinga.com Citizens Maintains Market Outperform on GH Research, Lowers Price Target to $39 Citizens analyst Jason N. Butler maintains GH Research (NASDAQ:GHRS) with a Market Outperform and lowers the price target from $42 to $39.
benzinga.com Earnings Scheduled For May 14, 2026 - benzinga.com GH Research Q1 EPS $(0.31) Misses $(0.28) Estimate GH Research (NASDAQ:GHRS) reported quarterly losses of $(0.31) per share which missed the analyst consensus estimate of $(0.28) by 10.71 percent. This is a 63.16 percent decrease over losses of…
globenewswire.com GH Research Reports First Quarter 2026 Financial Results and Provides Business Update Phase 2b results in TRD published in JAMA Psychiatry GH001-HV-106 study enrolment completed; doses selected for the global Phase 3 pivotal program of GH001 in TRD GH001-HV-109 US IND-opening study…- benzinga.com 'Health Officials Close To U.S. Secretary Kennedy Explored Ban Of Some Widely Used Antidepressants' - Reuters Exclusive Health officials explored restricting specific antidepressants among SSRI drugs-sources
- benzinga.com GH Research Prices ~$117.5M Offering Of 6.528M Shares At $18/Share GH Research PLC (NASDAQ:GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in depression, today announced…
globenewswire.com GH Research Announces Pricing of $117.5 Million Underwritten Offering DUBLIN, April 29, 2026 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing…
proactiveinvestors.com FTSE 100 Live: London stocks slide as aerospace and defence sector falls FTSE 100 down 35 points at 10,574 Markets await confirmation of US-Iran talks UK bond eyes developments in Westminster AB Foods, British Land,...
benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session 
benzinga.com Nektar Therapeutics, Compass Pathways, Sila Realty Trust And Other Big Stocks Moving Higher On Monday Nektar Therapeutics (NASDAQ: NKTR) rose on positive results for alopecia treatment. Other top gainers include AVEX, CMPS, ATAI, GHRS, POET, SILA, BLD, INV, MXL, KSPI.
globenewswire.com GH Research Welcomes White House Executive Order to Accelerate Medical Treatments for Serious Mental Illness DUBLIN, April 20, 2026 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing…
feeds.benzinga.com Enveric BioSciences Surges Over 90%, Other Psychedelic Stocks Soar In Monday Pre-Market: What's Going On? Psychedelic drug maker shares jumped in Monday pre-market after an order from President Donald Trump to speed up psychedelic drug reviews
benzinga.com Enveric BioSciences Surges Over 90%, Other Psychedelic Stocks Soar In Monday Pre-Market: What's Going On? Psychedelic drug maker shares jumped in Monday pre-market after an order from President Donald Trump to speed up psychedelic drug reviews
proactiveinvestors.com Psychedelics stocks rise after Trump order expands research, access pathways Shares of psychedelics-related stocks climbed in early trade on Monday after US president Donald Trump signed an executive order aimed at accelerating...
benzinga.com Why TopBuild Shares Are Trading Higher By 20%; Here Are 20 Stocks Moving Premarket TopBuild Corp (NYSE: BLD) rises in pre-market trading after QXO (NYSE: QXO) agrees to acquire for $17 billion. Shares jump 20.2% to $493.01.
defenseworld.net Comparing Prenetics Global (NASDAQ:PRE) & GH Research (NASDAQ:GHRS) Prenetics Global (NASDAQ: PRE - Get Free Report) and GH Research (NASDAQ: GHRS - Get Free Report) are both small-cap medical companies, but which is the better investment? We will compare the two…- benzinga.com 'Bipartisan Senators File Bill To Support Psychedelics Research And Treatment For Veterans' - Marijuana Moment https://www.marijuanamoment.net/bipartisan-senators-file-bill-to-support-psychedelics-research-and-treatment-for-veterans/
- benzinga.com GH Research Announces Two-Peer Reviewed Publications From Its Phase 2B Clinical Program Of GH001 For Treatment-Resistant Depression GH Research PLC (NASDAQ:GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in depression, today announced…
globenewswire.com GH Research Announces Publication of Phase 2b Results for Mebufotenin (GH001) in JAMA Psychiatry and Reports New Finding of Severity-Independent Efficacy in TRD DUBLIN, March 25, 2026 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing…
seekingalpha.com GH Research FY25 Results: Strong Cash Position As GH001 Advances Toward Phase 3 GH Research PLC remains well-capitalized with $280.7 million in cash, supporting its lead candidate GH001 for Treatment-Resistant Depression. GHRS's investment thesis centers on replicating strong…- benzinga.com Citizens Maintains Market Outperform on GH Research, Raises Price Target to $42 Citizens analyst Jason N. Butler maintains GH Research (NASDAQ:GHRS) with a Market Outperform and raises the price target from $39 to $42.
benzinga.com Needham Maintains Buy on GH Research, Raises Price Target to $32 Needham analyst Ami Fadia maintains GH Research (NASDAQ:GHRS) with a Buy and raises the price target from $31 to $32.- benzinga.com GH Research Q4 EPS $(0.23) Beats $(0.28) Estimate GH Research (NASDAQ:GHRS) reported quarterly losses of $(0.23) per share which beat the analyst consensus estimate of $(0.28) by 17.56 percent. This is a 35.29 percent decrease over losses of $(0.17)…
benzinga.com HC Wainwright & Co. Maintains Buy on GH Research, Raises Price Target to $70 HC Wainwright & Co. analyst Patrick R. Trucchio maintains GH Research (NASDAQ:GHRS) with a Buy and raises the price target from $35 to $70.- benzinga.com RBC Capital Maintains Outperform on GH Research, Raises Price Target to $40 RBC Capital analyst Brian Abrahams maintains GH Research (NASDAQ:GHRS) with a Outperform and raises the price target from $33 to $40.
- benzinga.com Canaccord Genuity Maintains Buy on GH Research, Raises Price Target to $39 Canaccord Genuity analyst Sumant Kulkarni maintains GH Research (NASDAQ:GHRS) with a Buy and raises the price target from $35 to $39.
- benzinga.com Needham Maintains Buy on GH Research, Raises Price Target to $29 Needham analyst Ami Fadia maintains GH Research (NASDAQ:GHRS) with a Buy and raises the price target from $19 to $29.
benzinga.com Dow Jumps 800 Points; ISM Manufacturing PMI Falls In December